PRP Injections for Genitourinary Syndrome of Menopause

Launched by MEDSTAR HEALTH RESEARCH INSTITUTE · Aug 31, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called platelet-rich plasma (PRP) injections to see if they can help improve sexual function in women experiencing genitourinary syndrome of menopause (GSM). GSM can cause discomfort, including vaginal dryness and irritation, which can affect sexual activity. The study aims to find out if injecting PRP into the vaginal area can make a difference for women who are sexually active and have been diagnosed with this condition.

To participate in the trial, women must be at least 18 years old, assigned female at birth, and should have had sexual activity at least once a week for the past month. Some women may not be eligible if they have certain medical conditions, such as pelvic organ prolapse or if they have had specific surgeries related to the pelvic area. Participants will receive the PRP injections and will be monitored to see how their sexual function improves over time. This study is currently recruiting participants, so if you meet the criteria and are interested, it could be a valuable opportunity to explore a new treatment option.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women (assigned female at birth) at least 18 years old with a clinical diagnosis of GSM
• • Sexually active with at least one episode of sexual activity per week in the preceding 4 weeks defined as follows: Partnered or solo penetrative or non-penetrative stimulation of the clitoris or vagina
• • English-speaking
• • Willingness and able to comply with the study requirements
• Exclusion Criteria:
• • Symptomatic pelvic organ prolapse protruding beyond the hymen)
• • History of prior vaginal mesh or midurethral mesh sling surgery
• • History of pelvic radiation or genital tract malignancy
• • Current symptomatic pelvic organ prolapse (stage II or greater)
• • Active vulvar dermatoses or genitourinary infection
• • Unable to hold anticoagulation
• • Hormonal replacement therapy (systemic, local, or vaginal) within 3 months of participation
• • Pregnancy or pre-menopausal status